

RESEARCH

Open Access

A BCL2 promoter polymorphism rs2279115 is not associated with BCL2 protein expression or patient survival in breast cancer patients

Claire J Searle^{1,2}, Ian W Brock¹, Simon S Cross³, Sabapathy P Balasubramanian⁴, Malcolm WR Reed⁴ and Angela Cox^{1*}

Abstract

The B-cell CLL/lymphoma 2 (BCL2) gene family encodes pro- and anti-apoptotic proteins that are critical regulators of programmed cell death. Higher levels of BCL2 expression in breast tumours have been shown to be an independent prognostic factor for improved survival from breast cancer. The promoter single nucleotide polymorphism (SNP) rs2279115 has been associated with both BCL2 expression and patient survival. The aim of this study was to attempt to replicate these observations in a cohort of 1015 UK women with breast cancer, and to compare genotype frequencies in cases and controls. In this study, 1015 breast cancer cases and 1034 control subjects were genotyped for the rs2279115 SNP by 5' nuclease PCR. Paraffin embedded tumour tissue for 342 case subjects was assembled into tissue microarrays, and the level of expression of BCL2 was established by immunohistochemistry. Kaplan Meier survival curves and Cox Proportional Hazards models were used to examine the effect of genotype on patient survival. The effect of SNP genotype on tumour BCL2 protein levels and breast cancer susceptibility was assessed by logistic regression. In this study higher BCL2 expression was significantly associated with improved survival from breast cancer ($p = 0.015$), in keeping with previous reports. The SNP rs2279115 was not found to be associated with tumour expression of BCL2, ($p = 0.77$), and neither was it associated with case/control status ($p = 0.25$). There was no significant association between the SNP and overall survival ($p = 0.75$). In conclusion, we found that higher tumour BCL2 expression is associated with improved survival from breast cancer, in keeping with previous studies. However, in contrast to a previous report, the promoter SNP rs2279115 was not associated with BCL2 expression or overall survival from breast cancer.

Keywords: Breast cancer, BCL2, rs2279115, Survival, SNP

Background

The balance between cell proliferation and levels of apoptosis is frequently disrupted in tumours, with tumorigenesis being promoted by both the loss of pro-apoptotic signals and the gain of anti-apoptotic mechanisms (Hanahan & Weinberg 2000; Hanahan & Weinberg 2011). The BCL2 family of proteins plays a crucial role in these processes, by integrating the complex pathways incorporating pro- and anti-apoptotic signals at the mitochondrial membrane (Tsujimoto 2002). The BCL-2 family can be categorised into anti-apoptotic and two

pro-apoptotic subgroups. The anti-apoptotic members include BCL2 and Bcl-xL. The pro-apoptotic members can be divided into a "multi-BH domain" group including Bax and Bak and a BH3-only subgroup (Adams & Cory 2002). However, BCL2 itself seems to act as both an oncogene and a tumour suppressor gene in different tumour types. For example, higher levels of tumour BCL2 expression are associated with poor patient survival from chronic lymphocytic leukaemia (CLL), but with improved survival from breast and colon cancer (Faderl et al. 2002) (Buglioni et al. 1999) (Callagy et al. 2008).

The *BCL2* gene consists of three exons and two promoters; it is located on chromosome 18q21.3. The SNP (rs2279115) is located in the inhibitory P2 promoter of

* Correspondence: a.cox@sheffield.ac.uk

¹Department of Oncology, CR-UK/YCR Sheffield Cancer Research Centre, University of Sheffield Medical School, Beech Hill Road, Sheffield, UK
Full list of author information is available at the end of the article

the *BCL2* gene (Park et al. 2004). The C allele in comparison to the A allele displayed significantly increased inhibition of *BCL2* promoter activity and binding of nuclear proteins (Nuckel et al. 2007). In keeping with these findings *BCL2* protein expression in B cells from CLL patients carrying the AA genotype was significantly increased compared with CC genotypes (Nuckel et al. 2007). This relationship was also demonstrated in relation to lymph node negative breast cancer in one previous study (Bachmann et al. 2007). In this study higher expression of *BCL2* was associated with the A-allele ($p = 0.044$) and Kaplan-Meier survival analysis revealed a significant association of the AA genotype with improved survival ($p = 0.030$). This relationship has also been demonstrated in oropharyngeal squamous cell carcinoma (Lehnerdt et al. 2009) where rs2279115 was significantly associated with *BCL2* expression ($p = 0.008$) and with overall survival ($p = 0.0247$). This trend was also demonstrated in renal cancer (Hirata et al. 2009).

Many studies have clearly demonstrated that increased *BCL2* expression is associated with improved outcome from breast cancer (Yang et al. 2003) (Callagy et al. 2006) (Callagy et al. 2008) (Dawson et al. 2010) (Ali et al. 2012). A multivariate analysis incorporating five published studies from 11,212 breast cancer cases strongly supported the independent prognostic significance of *BCL2* positivity with improved survival (Hazard Ratio (HR) 0.76, 95% Confidence Interval (CI) 0.54-0.74), $p < 0.001$ (Dawson et al. 2010). In addition, expression of *BCL2* has been proven to be an independent indicator of favourable prognosis for all types of early-stage breast cancer (Callagy et al. 2008; Dawson et al. 2010).

The aim of this study was to use a cohort of breast cancer cases, from the Sheffield Breast Cancer Study (SBCS) to determine whether there is a relationship between the promoter SNP rs2279115 and tumour protein levels of *BCL2*, and whether this corresponds to any differences in patient survival. We also confirmed the known association between high levels of tumour *BCL2* and improved survival from breast cancer.

Materials and methods

Subjects

Between November 1998 and January 2005, 1274 women with breast cancer and 1271 control subjects were enrolled in the SBCS. The design and methodology of this case control study have been previously described (Rafii et al. 2002) (Azmy et al. 2004). Briefly, all subjects were residents of South Yorkshire, UK and were of European descent. The breast cancer cases all had histopathologically confirmed breast cancer. The control subjects were women aged between 50 and 65 attending the Sheffield Mammography Screening Service between September 2000 and January 2004, whose mammograms showed no

evidence of breast lesions. The study was approved by the South Sheffield Research Ethics Committee (SSREC/98/137), and the DNA samples were collected with informed consent from subjects for their use in genetic studies of cancer. Paraffin-embedded tumour tissue was requested from the relevant NHS Histopathology Archive for 342 of the subjects recruited above. Pathological data (including tumour grade, morphology and lymph node status) were obtained from medical pathology records and validated (SSC). Immunohistochemical data for the oestrogen receptor (ER), progesterone receptor (PR), HER2 and cytokeratins 5/6 were available (Blows et al. 2010). Data on all-cause mortality and survival was obtained through the Trent Cancer Registry. Median follow-up for breast cancer cases in September 2009 was 21.6 years including 220 deaths.

Determination of *BCL2* rs2279115 genotype

Blood DNA samples were available from 1015 breast cancer subjects and 1034 controls. These were genotyped for the SNP rs2279115 using a Taqman 5' nuclease PCR assay. The Probe sequence was as follows 5'-CTCCCCAGGAGAGACAGGGGAGA[G/T]GGGACGATGAAGGAGCCGGGGACGG-3', with the FAM probe containing T and the VIC probe containing G. The amplification reaction was performed in a final volume of 5 μ L, with 1.0 μ L of genomic DNA (10 ng), 0.125 μ L of TaqMan™ Genotyping Assay, 2.5 μ L of Taqman Genotyping Master Mix, and 2.375 μ L of water. The thermo-cycling conditions were as follows: 95°C for 10 min followed by 60 cycles of 92°C for 10 s and 60°C for 1 min. Allelic discrimination was carried out using the ABI 7900HT Sequence Detector (Life Technologies) The overall genotype call rate was 96% (980 cases and 981 controls successfully genotyped), and duplicate concordance based on 133 duplicate samples was 99.25%. The observed control genotype frequencies were consistent with Hardy Weinberg equilibrium ($p = 0.76$).

BCL2 immunohistochemistry

Tissue micro arrays were constructed from 342 archived paraffin embedded tumour samples from the cancer cohort. Appropriate regions of tumour (judged by H.&E staining) were selected from the blocks and 0.6 mm triplicate tissue cores were punched out from these regions using a custom precision instrument (Beecher Instrument Inc., Sun Prairie, US). These were then transferred into recipient paraffin blocks in a specific orientation. 5 μ m sections from the array blocks were dried, deparaffinised and rehydrated before blocking endogenous peroxidase with a solution of 2% hydrogen peroxide in methanol. The sections were then subjected to antigen retrieval by microwave treatment in 10 mM tri-sodium citrate. This was

followed by a standard immunohistochemical staining procedure for BCL2 using a mouse monoclonal anti-human BCL2 antibody (Dako Code M0887) at a dilution of 1:50. The slides containing samples in triplicate were assessed for BCL2 signal intensity (by two independent observers (CJS and IWB) who were blinded to the genetic and clinical data) and scored semi-quantitatively. Each core on the microarray was given a score from zero (no stain) to 3 (high staining) depending on the intensity of the BCL2 staining from the tumour cells (Figure 1). The highest of the three triplicate scores for each tissue sample was used for statistical analysis. Agreement between the two independent observers was good as demonstrated by the Kappa statistic ($k = 0.81$).

Statistical analysis

All data was initially entered into a Microsoft Access database and exported to STATA 9.2 for statistical analysis. Data analysis was restricted to the 980 case and

981 control subjects for whom SNP genotypes were successfully called. Breast cancer epidemiological risk factors were assessed by Mann Whitney U test for continuous variables and by Pearson χ^2 test for binary variables. The relationship between BCL2 protein expression in tumours and SNP genotype, and that between SNP genotype and case/control status was assessed in a logistic regression model with AA as the reference genotype. Kaplan-Meier survival functions and Cox Proportional Hazards Regression models were used to assess the effects of variables on overall survival, using a left-truncated model to adjust for prevalent cases (Azzato et al. 2009). Overall survival was calculated from the date of first diagnosis to confirmed death or last known date of follow-up, up to a maximum of 10 years.

This project was designed and completed in accordance with the REMARK reporting recommendations for tumour MARKer prognostic studies (McShane et al. 2005).




Figure 1 Immunohistochemical evaluation of BCL2 protein expression in tissue microarrays of breast tumours. Tissue microarray cores illustrating the BCL2 immunohistochemistry scoring system. Panels A-D show zero (score 0), low (score 1), moderate (score 2) and high (score 3) BCL2 expression respectively.

Results

Subject characteristics

Table 1 shows the epidemiological characteristics of the cases and controls. There were no significant differences in the percentage of post-menopausal women, age at menarche or age at menopause between the cancer and control groups. However, the women in the control group were slightly younger compared to the cancer group (median interquartile range (IQR) of 57 (53–61) vs 59 (51–68); $p = 0.0004$). Control subjects were younger when first pregnant (median IQR of 23 (20–26) vs 24 (21–27) in the cancer group ($p = 1 \times 10^{-6}$), and had more children (median IQR of 2 (2–3) in the control group vs 2 (1–3) in the cancer group; $p = 0.01$). A higher proportion of cases had a positive family history of breast cancer compared to control subjects (14.5% vs 10.3%; $p = 0.005$).

The expected relationships were observed in case subjects for overall survival with tumour grade ($p = 1 \times 10^{-5}$) lymph node status ($P = 3.2 \times 10^{-10}$) (Figure 2).

Tumour BCL2 protein levels and overall survival

Following immunohistochemistry to detect BCL2 tumour samples on tissue microarrays, the median intensity score was 3 (range 0–3). Tumours with scores 0–1 were grouped together (low tumour expression of BCL2; $n = 35$), and the remaining two groups were score 2 (medium tumour expression of BCL2; $n = 68$) and score 3 (high tumour expression; $n = 145$). In accordance with previous reports, BCL2 tumour expression was significantly associated with survival ($p = 0.015$; hazard ratio (95% confidence interval) 0.69 (0.51 to 0.93); Figure 3).

BCL2 expression level in relation to lymph node status, grade, morphology, ER, PR, HER2, CK5/6 status and rs2279115 genotype

Tumour BCL2 protein expression scores were grouped into binary categories for comparison with standard prognostic variables including tumour grade, nodal status, ER, PR, HER2 and CK5/6 status (Table 2). The binary categories were scores 0–1 being low expression of BCL2 and scores 2–3 being high expression of BCL2. High tumour BCL2 protein expression was associated with lower grade of tumour ($p = 4 \times 10^{-9}$), presence of both oestrogen and progesterone receptor in tumours ($p = 1 \times 10^{-14}$ and 5×10^{-5} respectively), and lack of expression of CK5/6 ($p = 0.002$). There was no association with nodal involvement ($p = 0.54$), or morphology ($p = 0.68$). A higher proportion of HER2 positive tumours were BCL2-low but this was not statistically significant ($p = 0.07$).

There was no association between the level of expression of BCL2 and rs2279115 genotype (OR (95% CI) 0.83 (0.38, 1.82) and 1.23 (0.37, 4.10) for AC and CC genotypes, respectively, compared to AA genotype; Table 3).

Effect of rs2279115 on breast cancer susceptibility and overall survival


There was no difference in rs2279115 genotype frequencies between cases and controls; OR (95% CI) were 0.93 (0.76, 1.14) and 0.81 (0.63, 1.04) respectively for AC and CC genotypes compared to AA genotype (Table 4). Furthermore the rs2279115 SNP was not associated with overall survival, HR (95% CI) 1.03 (0.86, 1.24); $p = 0.75$

Table 1 Breast cancer risk factors in case and control subjects

Variable		Controls	Cases	p values
Age	N	981	980	
	Median (IQR)	57 (53–61)	59 (51–68)	$p = 0.0004^a$
Age at menarche	N	972	962	
	Median (IQR)	13 (12–14)	13 (12–14)	$p = 0.83^a$
Age at menopause	N	537	517	
	Median (IQR)	50 (47–52)	50(46–52)	$p = 0.62^a$
Age at first pregnancy	N	878	807	
	Median (IQR)	23 (20–26)	24 (21–27)	$p = 0.000001^a$
Parity	N	981	980	
	Median (IQR)	2 (2–3)	2(1–3)	$p = 0.01^a$
Menopausal status	N	981	978	
	post	679 (69.2%)	653 (66.8%)	
	pre	302 (30.8%)	325 (33.2%)	$p = 0.25^b$
Family history of breast cancer	N	981	980	
	Yes	101 (10.3%)	142 (14.5%)	
	No	880 (89.7%)	838 (85.5%)	$p = 0.005^b$

^a Mann Whitney U test. ^b Pearson χ^2 test. IQR: Inter-quartile range.

Positive family history was defined as the presence of at least one first degree relative with breast cancer.



(Figure 4). In addition, no statistically significant association was demonstrated between SNP genotype and survival in either lymph node negative or positive subjects (Figure 5; $p = 0.85$ and 0.24 respectively).

Conclusion

The *BCL2* family performs a cardinal role in the control of apoptotic pathways, regulating both cell death and cell survival mechanisms by altering mitochondrial membrane permeability and controlling the release of

cytochrome c (Reed 1994). Unfavourable outcomes were first reported in relation to inappropriate tumour *BCL2* protein expression in follicular lymphoma as a result of a chromosomal translocation $t(14,18)$ (Tsujimoto et al. 1984). It was the break point in this translocation that led to the discovery of the *BCL2* gene. The data presented here are consistent with previous reports that show that in breast cancer, in contrast to non-Hodgkins lymphoma, higher tumour protein expression of *BCL2* is associated with improved survival (Callagy et al. 2006)




Table 2 Level of BCL2 protein expression according to lymph node status, tumour grade, morphology, ER, PR, HER2 and CK5/6 status

		Low BCL2 n (%)	High BCL2 n (%)	p value ^a
Node status	No nodal Involvement	20 (64.5)	140 (70.0)	0.54
	Nodal Involvement	11 (35.5)	60 (30.0)	
Grade	1	3 (8.8)	51 (24.9)	4x10 ⁻⁹
	2	7 (20.6)	114 (55.6)	
	3	24 (70.6)	40 (19.5)	
Morphology	Ductal	28 (80.0)	159 (75.7)	0.68
	Lobular	2 (5.7)	22 (10.5)	
	Other	5 (14.3)	29 (13.8)	
ER status	Negative	27 (79.4)	31 (15.3)	1x10 ⁻¹⁴
	Positive	7 (20.6)	171 (84.7)	
PR status	Negative	20 (62.5)	53 (26.6)	5x10 ⁻⁵
	Positive	12 (37.5)	146 (73.4)	
HER2 status	Negative	29 (82.9)	193 (92.3)	0.07
	Positive	6 (17.1)	16 (7.7)	
CK5/6 status	Negative	23 (67.6)	180 (90.5)	0.0002
	Positive	11 (32.4)	19 (9.5)	

BCL2 immunohistochemistry scores were grouped into low (scores 0–1) and high (scores 2–3) ^a Pearson χ^2 test.

(Callagy et al. 2008) (Dawson et al. 2010). Anti-apoptotic BCL2 members act as repressors of apoptosis by blocking the release of cytochrome c, whereas pro-apoptotic members act as promoters (Ghobrial et al. 2005). The contrasting effect on survival of tumour BCL2 expression in breast cancer as opposed to non-Hodgkin lymphoma may well be due to the importance of the careful equilibrium between tumour BCL2 protein expression and other pro-apoptotic members such as Bax, rather than on BCL2 tumour protein quantity alone (Reed 1997) (Cory et al. 2003). Unfortunately the exact mechanism that underpins this difference is not fully understood. *In vitro* studies in a variety of different cell types have found that high levels of BCL2 protein expression in tumours can result in striking growth inhibition

Table 3 Level of BCL2 protein expression of according to rs2279115 genotype

Genotype	Low BCL2 n (%)	High BCL2 n (%)	Odds Ratio	95% CI	p value
AA	12 (13.3)	78 (86.7)	1.00		
AC	19 (15.6)	103 (84.4)	0.83	0.38 1.82	0.65
CC	4 (11.1)	32 (88.9)	1.23	0.37 4.10	0.74
TOTAL	35 (100)	213 (100.0)			

BCL2 immunohistochemistry scores were grouped into low (scores 0–1) and high (scores 2–3).

Table 4 Genotype frequencies for SNP rs2279115 in case and control subjects

Genotype	controls n (%)	cases n (%)	Odds Ratio	95% CI	p value
AA	290 (29.6)	314 (32.0)	1.00		
AC	475 (48.4)	477 (48.7)	0.93	0.76 1.14	0.47
CC	216 (22.0)	189 (19.3)	0.81	0.63 1.04	0.098
TOTAL	981 (100)	980 (100.0)			

(Pietenpol et al. 1994). In human breast cancer cell lines there is an inverse correlation between the expression of BCL2 and mutant p53 and that this relationship could lead to down-regulation of BCL2 tumour protein expression (Haldar et al. 1994). Other studies have suggested a function of BCL2 protein in lengthening the cell cycle (O'Reilly et al. 1996) (Knowlton et al. 1998) (Lipponen et al. 1995).

The relationship between tumour BCL2 protein expression and oestrogen has also been widely debated. It has been suggested that the intrinsic and extrinsic pathways which make up the two main routes involved in breast cancer cell apoptosis regulation, are both induced when oestrogen binds to the oestrogen receptor. Both pathways result in the activation of caspase leading finally to apoptosis (Lewis-Wambi & Jordan 2009). Leung and Wang found that a breast cancer cell line treated with the oestrogen 17 β -oestradiol resulted in up-regulation of BCL2 mRNA and protein, but down-regulation of Bcl-x(L) mRNA and protein. They did not find this result with other sex hormones. They speculated that different members of the BCL2 family proteins may be regulated through different pathways and that these pathways may be modulated by 17 β -oestradiol (Leung & Wang 1999). Tumour BCL2 protein expression status has also been previously strongly associated with PR and ER expression (Nadler et al. 2008) (Lee et al. 1997). Our data are consistent with previous observations that BCL2 is a strong independent prognostic marker for breast cancer survival (Dawson et al. 2010).

The SNP rs2279115 has been associated with BCL2 expression in CLL and breast cancer from node negative patients (Bachmann et al. 2007). The study by Bachmann et al. found that higher expression of BCL2 was associated with the A-allele (P=0.044) in lymph node negative patients only. This also corresponded to an improved survival in this group (HR (95% CI) 3.2 (1.03,9.93) p=0.044). Lymph node negative patients who were homozygous for the C allele had a higher risk of death than AA homozygous patients, with heterozygous women being intermediate in risk. In the present data we found no association between rs2279115 and tumour expression of BCL2 in the whole cohort, or when results were subdivided into




Figure 4 Kaplan-Meier survival functions according to rs2279115 genotype. Overall survival based on 934 case subjects with total time at risk 6765.43 years. Numbers at risk at the end of the 10-year analysis period were 158 (AA), 221 (AC), and 102 (CC). Hazard ratio (95% CI) 1.03 (0.86, 1.24), $p = 0.75$.

patient with lymph node positive or lymph node negative disease. We also found no association with survival for the different genotypes. Assuming a baseline survival proportion of 0.84 in lymph node negative cases, our study would have been expected to detect a hazard ratio of 3.2 between homozygous genotypes (as was found by Bachmann et al. 2007), having 80% power to detect hazard ratio of 1.8. However,

we are unable to exclude effects smaller than this. It is possible that there may be genotypic effects on survival of similar or smaller magnitude to those of BCL2 expression (Callagy et al. 2008; HR = 1.64); this study is underpowered to detect these.

In conclusion we have no evidence to support the SNP rs2279115 as a prognostic biomarker for breast cancer patients. Higher BCL2 expression has been




Figure 5 Kaplan-Meier survival functions in lymph node negative and positive subjects according to rs2279115 genotype. Overall survival based on 786 subjects with total time at risk 5808.75 years. **A** shows lymph node negative subjects and **B** shows lymph node positive subjects. Numbers at risk at the end of the 10-year analysis period were **A**: 103 (AA), 146 (AC), 79 (CC) and **B**: 38 (AA), 54 (AC), 18 (CC). Hazard ratios (95% CI) for **A** were 0.97 (0.73, 1.30), $p = 0.85$ and for **B** were 1.20 (0.88, 1.64), $p = 0.24$.

conclusively proven to correlate with improved survival and further studies are required to explore its use as a prognostic indicator.

Competing interest

The authors declare that they have no competing interests.

Authors' contribution

The study was designed by AC and MWR. Patient diagnosis and recruitment, and clinical data collection was carried out by MWR and SPB. Pathology data collection and generation of tissue microarrays was carried out by SSC. Genotyping, immunohistochemistry, and scoring of the immunohistochemical data was carried out by CJS and IWB. CJS and AC performed statistical analyses and CJS and AC drafted the manuscript. All authors read and approved the final manuscript.

Ethical standards

All experiments completed as part of this study comply with the current laws in the United Kingdom.

Acknowledgements

This project was supported by Yorkshire Cancer Research awards S295 and S299. We would like to thank all the women who took part in the SBCS, and Helen Cramp and Dan Connley for patient recruitment and data management respectively. CJS was funded by an Academic Clinical Fellowship from the UK National Institute of Health Research.

Author details

¹Department of Oncology, CR-UK/YCR Sheffield Cancer Research Centre, University of Sheffield Medical School, Beech Hill Road, Sheffield, UK.

²Department of Clinical Genetics, Chapel Allerton Hospital, Chapelton Road, Leeds, UK. ³Academic Unit of Pathology, Department of Neuroscience, University of Sheffield Medical School, Beech Hill Road, Sheffield, UK.

⁴Academic Unit of Surgical Oncology, CR-UK/YCR Sheffield Cancer Research Centre, University of Sheffield Medical School, Beech Hill Road, Sheffield, UK.

Received: 12 September 2012 Accepted: 17 September 2012

Published: 23 October 2012

References

- Adams J, Cory S (2002) The BCL2 family: regulators of the cellular life-or-death switch. *Nat Rev Cancer* 2:647–656
- Ali H *et al* (2012) A Ki67/BCL2 index based on immunohistochemistry is highly prognostic in ER-positive breast cancer. *J Pathol* 226(1):97–107
- Azmy IA *et al* (2004) Role of tumour necrosis factor gene polymorphism (–308 and –238) in breast cancer susceptibility and severity. *Breast Cancer Res* 6: R395–R400
- Azzato E *et al* (2009) Prevalent cases in observational studies of cancer survival: do they bias hazard ratio estimates? *BJC* 100:1806–1811
- Bachmann HS *et al* (2007) The AA genotype of the regulatory BCL2 promoter polymorphism (938C > A) is associated with a favorable outcome in lymph node negative invasive breast cancer patients. *Clin Cancer Res* 13:5790–5797
- Blows FM *et al* (2010) Subtyping of breast cancer by immunohistochemistry to investigate a relationship between subtype and short and long term survival: a collaborative analysis of data for 10,159 cases from 12 studies. *PLoS Med* 7(5):e1000279. doi:10.1371/journal.pmed.1000279
- Buglioni S *et al* (1999) Evaluation of multiple bio-pathological factors in colorectal adenocarcinomas: independent prognostic role of p53 and bcl-2. *Int J Cancer* 84:545–552
- Callagy GM *et al* (2006) BCL2 is a prognostic marker in breast cancer independently of the Nottingham Prognostic Index. *Clin Cancer Research* 12:2468–2475
- Callagy GM *et al* (2008) Meta-analysis confirms BCL2 is an independent prognostic marker in breast cancer. *BMC Cancer* 8:153
- Cory S, Huang DC, Adams JM (2003) The Bcl-2 family: roles in cell survival and oncogenesis. *Oncogene* 22(53):8590–8607
- Dawson SJ *et al* (2010) BCL2 in breast cancer: a favourable prognostic marker across molecular subtypes and independent of adjuvant therapy received. *Br J Cancer* 103(5):668–675

- Faderl S *et al* (2002) Expression profile of 11 proteins and their prognostic significance in patients with chronic lymphocytic leukemia (CLL). *Leukemia* 16:1045–1052
- Ghobrial IM, Witzig TE, Adjei AA (2005) Targeting apoptosis pathways in cancer therapy. *CA Cancer J Clin* 55:178–197
- Haldar S *et al* (1994) Down-regulation of bcl-2 by p53 in breast cancer cells. *Cancer Res* 54(8):2095–2097
- Hanahan D, Weinberg RA (2000) Hallmarks of cancer. *Cell* 100:57–70
- Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. *Cell* 144(5):646–674
- Hirata H *et al* (2009) The bcl2 -938CC genotype has poor prognosis and lower survival in renal cancer. *J Urol* 182(2):721–727
- Knowlton K *et al* (1998) Bcl-2 slows in vitro breast cancer growth despite its antiapoptotic effect. *J Surg Res* 76(1):22–26
- Lee HD, Koo JY, Jung WH (1997) Correlations of bcl-2 expression with clinicopathological features in breast cancer. *Yonsei Med J* 38(4):206–211
- Lehnerdt GF *et al* (2009) The regulatory BCL2 promoter polymorphism (–938C > A) is associated with relapse and survival of patients with oropharyngeal squamous cell carcinoma. *Ann Oncol* 20:1094–1099
- Leung LK, Wang TT (1999) Paradoxical regulation of Bcl-2 family proteins by 17beta-oestradiol in human breast cancer cells MCF-7. *Br J Cancer* 81(3):387–392
- Lewis-Wambi JS, Jordan VC (2009) Estrogen regulation of apoptosis: how can one hormone stimulate and inhibit? *Breast Cancer Res* 11(3):206
- Lipponen P *et al* (1995) Apoptosis suppressing protein bcl-2 is expressed in well-differentiated breast carcinomas with favourable prognosis. *J Pathol* 177(1):49–55
- McShane LM *et al* (2005) REporting recommendations for tumor MARKer prognostic studies (REMARK). *Nat Clin Pract Oncol* 2:416–422
- Nadler Y *et al* (2008) Expression patterns and prognostic value of Bag-1 and Bcl-2 in breast cancer. *Breast Cancer Res* 10(2):R35
- Nuckel H *et al* (2007) Association of a novel regulatory polymorphism (–938C > A) in the BCL2 gene promoter with disease progression and survival in chronic lymphocytic leukemia. *Blood* 109:290–297
- O'Reilly LA, Huang DC, Strasser A (1996) The cell death inhibitor Bcl-2 and its homologues influence control of cell cycle entry. *EMBO J* 15(24):6979–6990
- Park BL *et al* (2004) Identification of the variant in cyclin D1 (CCND1) AND B-cell CLL/lymphoma 2 (BCL2). *J Hum Genet* 49:449–454
- Pietenpol JA *et al* (1994) Paradoxical inhibition of solid tumor cell growth by bcl2. *Cancer Res* 54(14):3714–3717
- Rafii S *et al* (2002) A potential role for the XRCC2 R188H polymorphic site in DNA-damage repair and breast cancer. *Hum Mol Genet* 11:1433–1438
- Reed JC (1994) Bcl-2 and the regulation of programmed cell death. *J Cell Biol* 124(1–2):1–6
- Reed JC (1997) Bcl-2 family proteins: regulators of apoptosis and chemoresistance in hematologic malignancies. *Semin Hematol* 34:9–19
- Tsujimoto Y (2002) Bcl-2 family of proteins: life-or-death switch in mitochondria. *Biosci Rep* 22:47–58
- Tsujimoto Y *et al* (1984) Cloning of the chromosome breakpoint of neoplastic B cells with the t(14;18) chromosome translocation. *Science* 226(4678):1097–1099
- Yang Q *et al* (2003) Prognostic value of Bcl-2 in invasive breast cancer receiving chemotherapy and endocrine therapy. *Oncol Rep* 10:121–125

doi:10.1186/2193-1801-1-38

Cite this article as: Searle *et al.*: A BCL2 promoter polymorphism rs2279115 is not associated with BCL2 protein expression or patient survival in breast cancer patients. *SpringerPlus* 2012 1:38.